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Abstract During the past 15 years there has been an
expansion of our knowledge of the cellular and molecular
mechanisms regulating bone remodeling that identified
new signaling pathways fundamental for bone renewal as
well as previously unknown interactions between bone
cells. Central for these developments have been studies of
rare bone disorders. These findings, in turn, have led to new
treatment paradigms for osteoporosis some of which are at
late stages of clinical development. In this article, we
review three rare skeletal disorders with case descriptions,
pycnodysostosis and the craniotubular hyperostoses scle-
rosteosis and van Buchem disease that led to the devel-
opment of cathepsin K and sclerostin inhibitors,
respectively, for the treatment of osteoporosis.
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Introduction
Osteoporosis is characterized by the imbalance between
bone resorption by osteoclasts and bone formation by
osteoblasts that leads to loss and structural decay of bone
and, consequently, reduced bone strength and increased
fragility. This disturbance of bone remodeling provides the
rationale for the development of pharmacological agents to
prevent bone loss and reduce the risk of fractures in
patients with osteoporosis. The majority of currently
available treatments reduce bone resorption while only
PTH peptides stimulate bone formation. Although these
treatments have greatly improved the management of
patients with osteoporosis, they do not eliminate fracture
risk, have rather limited effect on the risk of nonvertebral
fractures, and they cannot build new bone at all sites
important for bone strength.
During the past 15 years there has been an expansion of
our knowledge of the cellular and molecular mechanisms
regulating bone remodeling that identified new signaling
pathways fundamental for bone renewal as well as previ-
ously unknown interactions between bone cells. Central for
these developments have been studies of rare bone disorders.
For example, the finding that loss-of-function mutations of
LRP5 cause the osteoporosis-pseudoglioma syndrome while
gain-of-function mutations of this receptor cause the High
Bone Mass phenotype revealed for the first time the impor-
tance of theWnt signaling pathway in bone formation [1–3].
Moreover, study of patients with osteopetrosis provided
evidence that bone resorption and bone formation are not
necessarily coupled if osteoclasts, despite losing their func-
tional ability, remain intact [4]. These findings, in turn, have
led to new treatment paradigms for osteoporosis some of
which are at late stages of clinical development. These new
treatments have been recently reviewed [5–7].
The relevant clinical question is whether, apart from
providing new treatment targets, study of patients with rare
skeletal disorders can improve our understanding of the
effects of new treatments on bone metabolism. In this
article, we address this question and we discuss three bone
dysplasias pycnodysostosis and the craniotubular hyper-
ostoses sclerosteosis and van Buchem disease, including
case descriptions, that led to the development of cathepsin
K and sclerostin inhibitors, respectively, for the treatment
of osteoporosis.
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Pycnodystostosis (OMIM 265800), meaning dense defec-
tive bone, is a rare, autosomal recessive osteochon-
drodysplasia. The first case was described in 1923 but the
features of the disease were defined by Maroteux and Lamy
in 1962 [8, 9]. The prevalence of pycnodysostosis is esti-
mated to be 1–1.7 per million, it is equally distributed
between women and men and about 200 cases have been
reported in the literature [10]. The disease is characterized
by osteosclerosis, short stature, acro-osteolysis of the distal
phalanges, clavicular dysplasia, skull deformities with
delayed suture closure, and bone fragility (Fig. 1a, b). The
most commonly described phenotype of pycnodystostosis
is short stature with increased bone mineral density and
increased bone fragility. In infants, open fontanels and
sutures with frontal and parietal bossing and hypoplasia of
the maxilla and mandible with an obtuse mandibular angle
are frequently seen. Dentogenesis with delayed eruption of
the teeth may also be present.
In a limited number of adequately evaluated bone
biopsies from patients with pycnodysostosis there was
cortical and trabecular osteosclerosis with increased corti-
cal width, findings consistent with the high values of BMD
of affected patients [11, 12]. Eroded surfaces were normal
or slightly increased with adjacent multinucleated osteo-
clasts but resorption lacunae were not deep and contained
unmineralized bone matrix (Fig. 1c, d). These observations
indicate dysfunction of osteoclasts that are unable to digest
the collagenous bone matrix after the dissolution of the
mineral in the resorption space. Bone formation was
decreased but osteoid thickness was low, normal, or
increased possibly due to differences in the age of the
studied patients. Tetracycline labels were decreased but
present in bone biopsies. Lamellar organization was dis-
turbed to varying degrees and mineralized cartilage resid-
uals were observed to a lesser extent than in cases of
osteopetrosis. It was suggested that these disturbances of
the quality of bone matrix may contribute to bone fragility
in pycnodysostosis [12].
The cause
In 1995, Gelb and colleagues performed a genome-wide
search in a large consanguineous Israeli Arab family with
16 affected individuals, identified the locus of pycn-
odysostosis to chromosome 1q21, and found a mutation in
the gene encoding cathepsin K by positional cloning [13].
These authors also provided further evidence that cathepsin
K deficiency causes pycnodysostosis by finding additional
mutations in two unrelated Mexican and American-His-
panic families. Notably, these observations coincided with
the elucidation of the localization of cathepsin K in
osteoclasts and its action in bone resorption [14–16]. Fur-
ther studies of patients with pycnodysostosis confirmed
these original findings and revealed the presence of at least
Fig. 1 Pycnodysostosis: a Open sutures; b Acro-osteolysis; c Iliac
crest bone biopsy showing cortical (Ct) and trabecular osteosclerosis
(from [11]); d High magnification of an iliac crest bone biopsy
showing an osteoclast adjacent to a resorption lacuna filled with
unmineralized matrix (from [12]); SEM images of odanacatib-treated
osteoclast culture on dentine slides: e Control, showing a deep
resorption pit; f Treated, showing discrete, small, shallow resorption
pits (from [87])
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35 different mutations in the cathepsin K gene with no,
however, clear genotype-phenotype associations.
Cathepsin K, a member of a family of cysteine proteases
with shared sequence and structural homology, is respon-
sible for the digestion of the organic matrix of bone [17]. It
is synthesized as a pro-enzyme before being transported to
lysosomes where it is cleaved to produce the active
enzyme. Cathepsin K is abundantly expressed in osteo-
clasts, but has also been detected in macrophages and bone
marrow-derived dendritic cells, but hardly in splenic T
cells [18]. In mature osteoclasts, cathepsin K is essential
for osteoclast-mediated bone resorption because it
degrades collagen type I and other bone matrix proteins
[19–21]. The enzyme cleaves the N-telopeptide, generating
NTX and degrades C-terminal telopeptide of type I colla-
gen (1CTP), producing CTX [17]. In line with these actions
of cathepsin K and consistent with the histological findings,
patients with pycnodysostosis have normal serum TRAP5b
values, a marker of osteoclast number, while serum NTX
and CTX values are low and those of serum 1CTP are
increased [22].
Mice deficient in cathepsin K had osteosclerosis in the
presence of fully differentiated osteoclasts while mice
overexpressing cathepsin K had decreased trabecular bone
volume and increased bone turnover [23, 24]. Bone biop-
sies from cathepsin K-deficient mice confirmed the
decreased bone resorption and revealed the presence of
increased osteoclast numbers with maintenance, however,
or increase in bone formation [25]. To elucidate the
mechanism of action of cathepsin K in bone remodeling,
particularly in bone formation, the enzyme was deleted in
hematopoietic cells or specifically in osteoclasts and cells
of the monocyte-osteoclast lineage and resulted in
increased bone volume. This increase in bone volume was
accompanied by an increase in bone formation rates as well
as in osteoclast and osteoblast numbers [26]. However, in
the same study, deletion of cathepsin K in osteoblasts had
no effect on bone turnover or bone formation rates [26],
demonstrating that the increase in bone formation was
driven by the osteoclasts. These observations confirmed
that in the absence of cathepsin K, bone resorption and
formation are not coupled and that there are signals from
osteoclasts to the osteoblast lineage (e.g. SP1) that main-
tain bone formation in the presence of decreased bone
resorption. In addition, matrix-derived factors that can
stimulate bone formation (e.g. IGF1) and are not degraded
due to the lack of cathepsin K may be contributory [27].
The patient
A 34-year-old female of Indian origin was investigated for
the first time at the age of 11 years for delayed growth and
at the age of 15 years the diagnosis of osteopetrosis was
made by a pediatric endocrinologist. Parents were con-
sanguineous, she had a brother and a sister who were
healthy. She was seen for the first time in our institution at
the age of 16 years. She had no specific complaints, no
vision or hearing problems and had never sustained a
fracture. At the age of 19, she had an adjustment operation
of the maxilla to improve its form and her eating. Her
height was 140.5 cm, weight 35 kg, blood pressure
100/55 mm Hg, and pulse rate 76/min. She had microg-
nathia but clinical examination was otherwise unremark-
able and she had no hepatosplenomegaly. Serum
25-hydroxyvitamin D was low (25 nmol/l) with a slightly
raised plasma PTH (9.5 pmol/l); both these abnormalities
were corrected with vitamin D supplementation. Serum and
urinary calcium excretion and serum phosphate were
always within the normal range. Serum alkaline phos-
phatase was always normal for age: 146 U/l at 16 years,
102 U/l at 19 years, 109 U/l at 20 years, 69 U/l at 23 years,
and 69 U/l at 25 years (normal adult range 40–120 U/l). In
addition, serum P1NP, another marker of bone formation,
was 68 ng/ml (upper limit of normal range) at the age of
25 years. BMD was increased (femoral neck Z-score ?3.3,
lumbar spine Z-score ?1.2) but did not increase further
with time, and skeletal radiographs showed diffuse
osteosclerosis, mandibular hypoplasia, and mild acro-
osteolysis of the phalanges. DNA testing revealed a
homozygous missense mutation of the CTSK gene (exon 6
p.Ile249Thr). Histomorphometry of a transiliac bone
biopsy was consistent with previous reports.
This patient with cathepsin K deficiency had typical
phenotypic, radiographic, and histological features of
pycnodysostosis but she had never experienced a fragility
fracture. Increased bone fragility is always mentioned as a
typical feature of pycnodysostosis. However, this appears
not to be the case. In a detailed description of 16 patients
from different families with 8 different mutations, all had
short stature, 14/16 had acro-osteolysis while 8/16 had
fractures as was also reported in a smaller study [10, 28]. In
a review of published cases, fractures were reported in
67 % of patients [29]. The reason for the lack of bone
fragility in our patient is not clear and does not appear to be
directly related to the changes observed in bone biopsy.
Furthermore, bone formation markers were always normal
for age over a period of 11 years, consistent with reports of
normal values of biochemical markers of bone formation in
patients with pycnodystostosis [22, 30].
Cathepsin K inhibitors
The discovery that in cathepsin K deficiency, contrary to
treatments with antiresorptive medications (e.g. bisphos-
phonates, denosumab), the decrease of bone resorption was
associated with ongoing bone formation supported the
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development of a new class of antiresorptive agents tar-
geting cathepsin K [31].
Animal studies
A number of cathepsin K inhibitors were synthesized and
were tested in preclinical studies. In vitro studies showed
inhibition of osteoclastic bone resorption and formation of
shallow resorption pits (Fig. 1e, f). However, rodents that
are used extensively in the development of antiosteoporotic
drugs could not be used in in vivo preclinical studies of
cathepsin K inhibitors due to differences in amino acid
sequence between rodent and human cathepsin K. Most of
the preclinical studies with cathepsin K inhibitors were
performed in primates. In addition, a rabbit model, which,
in contrast to rodents, undergoes cortical Haversian
remodeling, was used in several studies. In OVX primates,
cathepsin K inhibitors act differently from bisphosphonates
and denosumab. Whereas treatment with relacatib,
odanacatib, or ONO-5334 reduced bone resorption in OVX
monkeys, it also increased the number of non-resorbing
osteoclast at the bone surfaces and, depending on the bone
envelope, decreased, maintained, or even increased bone
formation [32–34]. For example, odanacatib treatment
reduced trabecular and intracortical bone formation while it
preserved endocortical bone formation and increased
periosteal bone formation in the femoral neck, proximal
femur, and central femur; the latter effect was also
observed in the mid-shaft femur of OVX monkeys treated
with balicatib [35, 36]. These changes were associated with
increases in volumetric BMD of both trabecular and cor-
tical bone and increases in cortical area of the femoral neck
and cortical thickness of the proximal tibia. Importantly,
the increases in bone mass were positively and significantly
related with bone strength. The mechanism(s) responsible
for the site-specific effect of cathepsin K inhibitors on bone
formation has not yet been elucidated and its relevance in
humans remains to be established [37]. Interestingly,
excess periosteal bone formation over resorption, possibly
supernormal, was reported in a detailed rib biopsy from a
patient with pycnodystostosis [38].
In OVX rabbits, odanacatib reduced bone resorption,
preserved bone formation in trabecular and endocortical
surfaces, increased hip BMD dose-dependently, and
improved biomechanical properties of the vertebrae and the
central femur [39, 40]. Furthermore, odanacatib did not
impair callus formation or its biomechanical integrity in a
rabbit model of fracture healing [41]. A recent study
reported that while odanacatib restored trabecular BMD,
microstructure and biomechanical properties, and increased
bone formation and cortical thickness of the central femur
in osteopenic rabbits, it also led to loss of crystal hetero-
geneity that appeared to contribute to cortical brittleness
[42]. The latter report, that contrasts all other observations,
needs to be confirmed in further studies.
Human studies
Clinical testing of the earlier developed cathepsin K inhi-
bitors relacatib and balicatib was interrupted because of
lack of specificity for cathepsin K (relacatib) or accumu-
lation in lysosomes of cells other than the osteoclasts
(lysosomotropism) leading to off-target effects (balicatib).
Odanacatib and ONO-533, however, did not show any
evidence of off-target effects in initial clinical studies [43–
45].
The efficacy and safety of ONO-5334 and odanacatib
were assessed in phase 2 clinical trials in postmenopausal
women with low bone mass. Both cathepsin K inhibitors
were administered orally, without regard to food intake,
either daily (ONO-5334) or once-weekly (odanacatib).
Adverse, off-target, effects such as morphea-like lesions
and infections, previously observed with balicatib treat-
ment, were not observed in either of these clinical trials.
Two-year treatment with ONO-5334, 300 mg per day,
reduced urinary NTX/Cr by 66 % while serum BASP
levels returned to baseline following an initial decline of
13 % [45]. In addition, ONO-5443, contrary to alen-
dronate, did not reduce serum TRAP5b levels. BMD of the
spine and hip increased by 6.7 and 3.4 %, respectively.
A two-year, phase 2 dose-finding clinical trial of oda-
nacatib was extended for an additional 3 years [43, 44].
Compared with baseline, 5-year treatment with odanacatib
50 mg once-weekly reduced biochemical markers of bone
resorption by about 55 % while markers of bone formation
after an initial decrease returned to baseline values. As
expected by the mechanism of action of the inhibitor,
serum levels of TRAP5b and 1CTP increased (Fig. 2) [45].
Odanacatib treatment was associated with continuous
increases in BMD by 11.9, 8.5, and 9.8 % at the spine, total
hip, and femoral neck, respectively. Odanacatib given for 2
years was further shown to increase volumetric BMD and
estimated bone strength at both the hip and the spine in
postmenopausal women [46–48]. Rates of adverse events
were similar between placebo- and odanacatib-treated
women. The action of odanacatib on BMD and bone
turnover markers was reversible. Following discontinuation
of odanacatib, there was a transient rebound of the levels of
biochemical markers of bone turnover followed by
decreases of BMD to baseline values; a response different
from that following discontinuation of bisphosphonate
treatment but similar to that after discontinuation of
denosumab.
A phase 3 placebo-controlled, event-driven clinical trial
with a preplanned extension was designed to assess the
anti-fracture efficacy and safety of odanacatib in
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postmenopausal osteoporosis (LOFT trial) [49]. In total,
16,713 women with osteoporosis were randomized to
receive placebo or odanacatib 50 mg one-weekly. In July
2012, the study was terminated on the recommendation of
an independent Data Monitoring Committee (DMC)
because of efficacy and a favorable benefit/risk profile of
odanacatib relative to placebo. The DMC also recom-
mended that additional safety data should be obtained in
the preplanned, blinded extension study. Compared with
placebo, treatment with odanacatib decreased significantly
the incidence of new and worsening morphometric verte-
bral fractures by 54 %, of hip fractures by 47 %, of non-
vertebral fractures by 23 %, and of clinical fractures by
72 % [50]. Odanacatib treatment led to progressive
increases in BMD at lumbar spine and total hip: 11.2 %
and 9.5 %, respectively, versus placebo over 5 years.
Adverse events were generally well balanced between
groups. Adjudicated morphea-like skin lesions occurred
more frequently in odanacatib-treated patients (n = 12) vs
placebo (n = 3) and resolved/improved after study drug
discontinuation. Adjudicated femoral shaft fractures with
atypical features occurred only in odanacatib-treated
patients (n = 5) while no cases of ONJ were reported. No
meaningful differences between groups were observed in
adjudicated systemic sclerosis, respiratory infections, or
delayed fracture union. Major cardiovascular events were
generally balanced; however, there were numerically more
adjudicated strokes with ODN than with placebo; final
blinded adjudication of major cardiovascular events is
ongoing [50].
Comment
Deficiency of cathepsin K in humans, as it occurs in pyc-
nodysostosis, is associated with high BMD but also
increased bone fragility in about half of the patients. On the
other hand, inhibition of cathepsin K in animal models
increased bone mass and strength, and initial results of
human studies demonstrated increases in BMD associated
with significant reduction of fracture risk. Thus, while the
human disease provided an excellent model for the
identification of cathepsin K and its importance in bone
resorption could not fully predict the effects of cathepsin K
inhibition in humans with osteoporosis. In interpreting
these findings it is important to differentiate the life-long
complete and permanent effect of cathepsin K deficiency
on the skeleton as opposed to its short-term, transient, and
reversible inhibition in subjects with low bone mass. In
addition, lack of a skeletal phenotype in heterozygote
carriers of pycnodysostosis indicates that the degree of life-
long inhibition of cathepsin K may be important. Results of
the long-term effects of treatment of humans with cathep-
sin K inhibitors will help to fully clarify this issue.
Sclerosteosis
Sclerosteosis (OMIM 269500) is a very rare, autosomal
recessive bone sclerosing dysplasia belonging to the group
of craniotubular hyperostoses. It was first described as
‘‘osteopetrosis with syndactyly’’ by Truswell in 1958 and
the term osteosclerosis was coined by Hansen in 1967 [51,
52]. About 100 cases have been reported in the literature,
mainly in members of the Afrikaner community in South
Africa. In this population, the estimated carrier rate is high
being 1 in 140 individuals. The disease is characterized by
bone overgrowth and generalized osteosclerosis. Affected
patients are tall for age, and clinical manifestations are
most pronounced in the mandible and the skull with
characteristic enlargement of the jaw and facial bones
leading to facial distortion and cranial nerve deficits such
as hearing loss (100 %) and facial palsy (89 %), and less
frequently loss of vision or smell (Fig. 3a). The most
severe and life-threatening complication of sclerosteosis is
increased intracranial pressure mainly as a result of
decreased intracranial volume due to the thickening of the
calvaria and the skull base. In the past, this has been a
common cause of sudden death of patients with scleros-
teosis. Patients with sclerosteosis have, in addition, digit
malformation such as syndactyly (52 %) and nail hypo-
plasia (63 %) (Fig. 3b). The disease is progressive but
clinical signs and symptoms stabilize after the third decade
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% Fig. 2 Percent changes of
biochemical markers in serum
of women treated with
odanacatib 50 mg once weekly
for 5 years. Open bars baseline;
Closed bars 5 years (from [5])
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of life [53]. It is noteworthy, that apart from the charac-
teristic skeletal changes, the general health of patients with
sclerosteosis is otherwise good.
Skeletal radiographs show dense bones and cortical
hyperostosis resulting from increased endosteal thickening
of tubular bones. These changes are reflected in greatly
increased BMD values at the hip and the spine with Z
scores sometimes exceeding ?10 [54]. In contrast to
osteopetrosis, fractures have never been reported in
patients with sclerosteosis [53, 55]. In a small number of
bone biopsies obtained from patients with sclerosteosis,
bone formation was greatly increased in trabecular and
cortical bone (Fig. 3c) [53, 56]. The newly laid bone was
lamellar with no mineralization defect; data on bone
resorption were variable with decrease or no change in
bone resorption. Bone material composition evaluated in
surgically obtained specimens of compact bone showed
reduction of bone matrix mineralization with increased
heterogeneity of mineralization [57].
In patients with sclerosteosis, biochemical markers of
bone formation show a normal, age-related pattern,
increasing during childhood and adolescence to levels,
however, higher than in healthy controls and declining after
the completion of the growth spurt to levels around the
upper limit of the normal adult range [53]. Biochemical
markers of bone resorption follow a similar pattern but
remain within their respective normal values. No abnor-
malities have been reported in serum calcium, phosphate,
and PTH concentrations.
The cause
In 2001 two groups independently identified mutations in a
new, rather small gene named SOST located on chromo-
some 17q12-21 that encodes for the protein sclerostin [58,
59]. At least 8 different mutations of the SOST gene have
been reported leading to loss-of-function of sclerostin.
Sclerostin is a glycoprotein with a cystine knot and three
loops that is synthesized in the skeleton exclusively by
mature osteocytes and inhibits bone formation at the bone
surface by antagonizing the Wnt signaling pathway [60,
61]. Sclerostin binds to the first propeller of the LRP5/6
receptor and disables the formation of the co-receptor
complex between LRP5/6 and the frizzled receptor. The
action of sclerostin on the Wnt signaling pathway is
facilitated by LRP4 [62, 63]. SOST mRNA is expressed in
many tissues, especially during embryogenesis, but scle-
rostin is expressed postnatally only in terminally
Fig. 3 Sclerosteosis: a Enlarged skull and mandible with facial
palsy; b Syndactyly; c Biopsy of compact bone with high numbers of
osteoblasts and osteoid van Buchem disease: d Typical features with
facial palsy; e Petrous part of temporal bone and acoustic meatus
(arrows) of a normal skull (upper) and of a skull of a patient (lower);
note the increased thickening and the narrowing of the meatus (from
[88]); f Increased bone formation in a biopsy from compact bone
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differentiated cells embedded within a mineralized matrix
(osteocytes, mineralized chrondocytes and cementocytes).
Consistent with this restricted expression of sclerostin,
patients with sclerosteosis have no renal or cardiovascular
abnormalities. Sclerostin in addition to its action on bone
formation, stimulates the production of RANKL from
neighboring osteocytes and increases bone resorption [64–
66]. The production of sclerostin is regulated by different
factors the most important being mechanical loading, PTH
and estrogens, all of which reduce the production of scle-
rostin by osteocytes (Fig. 4) [67]. As expected, sclerostin
was not expressed in bone biopsies from patients with
sclerosteosis.
Targeted deletion of the Sost gene in mice increased
bone mineral density at all skeletal sites and bone strength
while mice overexpressing Sost were osteopenic [68, 69].
BMD increased progressively from 1 to 4 months of age,
continuously but at a slower rate between 4 and 12 months
and maintained a peak up to 18 months. MicroCT and
histological analyses showed doubling of trabecular bone
volume and thickness of the distal femur and of the cortical
area of the femoral shaft due to increased rate of bone
formation at all skeletal envelopes (trabecular, endocortical
and periosteal) while osteoclast surface was not different
from that of wild-type animals [68]. Similar to humans,
bone matrix mineralization was reduced in sclerostin
deficient mice [57]. There was, thus, a remarkable
concordance of the findings in humans and mice with
sclerostin deficiency.
Van Buchem disease
The disease (OMIM 239100) was first described by van
Buchem et al. in 1955 as ‘‘hyperostosis corticalis gener-
alizata familiaris’’ [70]. It is a very rare, autosomal reces-
sive craniotubular hyperostosis phenotypically very similar
to sclerosteosis (Fig. 3d). There are about 30 known cases,
the vast majority inhabitants of a small fishing village in
the Netherlands. The carrier rate of the disease is unknown.
Clinical manifestations of 15, recently evaluated patients
with van Buchem disease, included facial palsy in all,
various degrees of hearing impairment in 14/15 patients
(Fig. 3e), symptoms of increased intracranial pressure in
3/15 patients, decreased sense of smell in 2/15 patients
while none had visual impairment [71]. Different from
patients with sclerosteosis, those with van Buchem disease
have normal height and no digit abnormalities (Table 1).
The clinical course of the disease stabilized in adulthood
and no patient reported symptoms related to other organs
such as heart, lungs, urogenital or gastrointestinal tract.
Skeletal radiographs and CTs showed changes very similar
to those of patients with sclerosteosis and BMD was
greatly increased at both lumbar spine the hip with
Z-scores ranging between ?5.0 and ?12.0. Serum P1NP
values declined with age, as in patients with sclerosteosis,
but remained either elevated or close to the upper limit of
normal in adults. Laboratory investigations revealed no
abnormalities in hematology or mineral metabolism. In a
few bone biopsies from patients with van Buchem disease
increased bone formation was documented (Fig. 3f) and
lack of sclerostin expression in osteocytes. However, in one








Fig. 4 Schematic representation of sclerostin actions. Osteocyte-
produced sclerostin inhibits the proliferation, differentiation and
survival of osteoblasts and reduces bone formation; it stimulates also
the production of RANKL by neighboring osteocytes and bone
resorption. In osteoblasts, sclerostin binds to LRP5/6 and inhibits the
Wnt signaling pathway, an action facilitated by LRP4. Production of
sclerostin is decreased by mechanical loading, PTH, estrogens and
other factors (from [67])
Table 1 Similarities and differences of Sclerosteosis and van
Buchem disease
Characteristic Sclerosteosis van Buchem disease
Genetic defect Mutation SOST 52-kb deletion SOST
Inheritance Autosomal recessive Autosomal recessive
Stature Tall Normal
Syndactyly Common Absent
Facial palsy Common Common
Hearing loss Common Common
Increased ICP Common Uncommon
BMD Increased Increased
Serum Sclerostin Undetectable Very low
ICP intracranial pressure, BMD bone mineral density
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The cause
In patients with van Buchem disease, there were no muta-
tions in the SOST gene but a 52-kb homozygous noncoding
deletion 35 kb downstream of the SOST gene was identified
[72, 73]. The deleted region contains a regulatory element
particularly important for the gene transcription in bone but
is not required for its embryonic transcription. These
observations may explain the similar bone phenotypes of
van Buchem disease and sclerosteosis and the absence of
digit abnormalities in patients with van Buchem disease. In
mice targeted deletion of ECR5, a bone enhancer located in
the van Buchem deletion, increased bone mass and bone
formation rates in trabecular bone with no effect on bone
resorption and improved bone structure [74]. These changes
were less pronounced than in Sost knock-out mice a finding
consistent, according to authors, with the milder phenotype
of van Buchem disease.
The patient
The patient, a male of Dutch origin, presented at the age of
3 years with facial palsy and developed progressive deaf-
ness requiring a hearing aid by the age of 10 years fol-
lowed by bilateral bone-anchored hearing aids [75]. He had
a large skull and mandible but no abnormalities of hands or
digits. He has been otherwise well with normal growth
development. He was tall for age (above the 90th per-
centile, but both parents were also tall). He had three,
phenotypically normal, sisters. During 15-year follow-up
he had no signs or symptoms from other organs, and blood
pressure was normal. Hematology and biochemistry,
including parameters of mineral metabolism, demonstrated
no abnormalities over the years. Skeletal radiographs
showed thickening of the calvarium, the base of the skull
and of the long bones and sclerosis of the vertebrae. Bone
mineral density (BMD) of the spine and hip were markedly
increased (Z-score ?7.2). Spine BMD of the parents was
also on the high side; the mother had a Z-score of ?0.98
and the father of ?0.85. Biochemical markers of bone
turnover were always increased compared to normal values
for age, but followed a normal pattern of change with a
further increase during the growth spurt and a progressive
decline thereafter, although never reaching the normal
range. The diagnosis of van Buchem disease was confirmed
by the finding of a 52-kb homozygous deletion 35 kb
downstream of the SOST gene on chromosome 17q12-q21.
Both parents were carriers of the disease.
Sclerostin inhibitors
The restricted expression of sclerostin to the skeleton and
the lack of abnormalities in organs other than the skeleton
in patients with sclerostin deficiency made this protein an
attractive target for the development of a new bone forming
therapy for the management of osteoporosis. This approach
was further supported by the gene-dose effect suggested by
findings in heterozygous carriers of sclerosteosis who
demonstrated decreased serum sclerostin levels associated
with increased levels of P1NP and high normal or
increased BMD without any clinical symptoms, signs, or
complications of sclerosteosis [53, 54]. The most fre-
quently used sclerostin inhibitor in preclinical and clinical
studies is romosozumab (AMG 785, a humanized mono-
clonal antibody) while blosozumab (humanized mono-
clonal antibody) has also been used in clinical studies.
Animal studies
In OVX rats and nonhuman primates, injections of scle-
rostin antibody (Scl-Ab) increased dramatically the rate of
bone formation at all skeletal envelopes and bone mass and
strength at multiple sites [76–78]. Importantly, the majority
of new bone formation was modeling-based occurring at
quiescent surfaces, a true anabolic response [79]. The
increase in bone formation induced by Scl-Ab was not
associated with an increase in bone resorption. Instead, a
decrease of osteoclast surface was observed, suggesting a
functional uncoupling between bone formation and bone
resorption. Despite increases of 54 % in bone volume,
matrix mineralization was not affected [80]. The effect of
sclerostin inhibition on bone formation was reversible upon
discontinuation of treatment.
Human studies
In phase 1 human studies, administration of single or
multiple doses of romosozumab and blosozumab increased
bone formation markers and decreased bone resorption
markers associated with significant increases in BMD [81,
82]. A phase 2 clinical trial of the efficacy and tolerability
of romosozumab in postmenopausal women with low bone
mass compared different doses and dosing intervals of
subcutaneous injections of romosozumab with placebo,
oral alendronate 70 mg weekly, and subcutaneous teri-
paratide 20 lg daily [83]. Romosozumab, 210 mg once-
monthly sc, increased BMD at the spine (11.3 %), total hip
(4.1 %), and femoral neck (3.7 %) (Fig. 5). These increa-
ses were significantly higher than those observed in women
treated with either alendronate or teriparatide. No differ-
ences in BMD of the distal third of the radius were
observed between any of the studied groups. Adverse
events were similar between groups except for mild reac-
tions at the injection sites of romosozumab. Continuation
of romosozumab treatment for a second year was associ-
ated with further increases in spine and total hip BMD to
Endocrine (2016) 52:414–426 421
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total gains of 15.7 and 6.0 %, respectively, while serum
P1NP and CTX levels remained below baseline values
[84]. Women were then randomized to receive denosumab
or placebo for an additional year. Women who transitioned
to denosumab continued to accrue BMD at a rate similar to
that with romosozumab during the second year, while in
those who transitioned to placebo BMD returned towards
pretreatment levels; similar results were reported after
discontinuation of one year blosozumab treatment [85].
Kinetics of biochemical markers of bone turnover during
treatment with romosozumab were intriguing and different
from those observed during treatment of patients with other
antiosteoporotic agents (Fig. 6) [86]. Therewas an early rapid
increase in bone formationmarkers followed by a progressive
decline with time, which was not due to the development of
neutralizing antibodies. The effect of sclerostin inhibition on
bone formation markers was further associated with a
decrease of bone resorption markers, possibly through an
inhibitory effect of the antibodyon the productionofRANKL/
OPG by the osteocytes [64]. Treatment prolongation, how-
ever, appears to modestly reduce bone resorption but also
bone turnover. It is postulated thatwhile romosozumab acts as
pure anabolic agent in the beginning of treatment, prolonged
administration results in mild inhibition of bone resorption
and reduction of the remodeling space. Themechanismof this
response has not yet been clarified. Phase 3 clinical studies are
currently investigating the anti-fracture efficacy and tolera-
bility of romosozumab versus placebo or bisphosphonate in
patients with osteoporosis (www.clinicaltrials.gov) and the
first results are expected in 2016.
Comment
Outcomes of studies of human and animal sclerostin defi-
ciency are remarkably similar and were reproduced in
preclinical and clinical studies with sclerostin inhibitors





























0 3 6 12 
ROMO ALN TPTD Placebo 
-0.1% 
-0.7% 
Fig. 5 Percent changes of lumbar spine and total hip BMD during
treatment of women with low bone mass with romosozumab (ROMO)
210 mg once-monthly sc, teriparatide (TPTD) 20 lg daily sc,
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Fig. 6 Schematic
representation of changes in
levels of serum biochemical
markers of bone formation
(P1NP) and bone resorption
(CTX) during treatment with
subcutaneous injections of
either teriparatide (TPTD, 20 lg
daily) or romosozumab
(ROMO, 210 mg once monthly)
for 1 year (from [86])
Table 2 Consistency of
findings in patients with
sclerostin deficiency and
treatment of animals and
humans with sclerostin antibody
Sclerosteosis Scl-Ab animals Scl-Ab humans
Bone mass Increased Increased Increased
Bone strength Increased Increased Increaseda
Bone formation Increased Increased Increasedb
Bone resorption Normal or decreased Decreased Decreasedb
Anabolic response Decreases with age Declines with time Declines with time
a Assessed by finite element analysis
b Assessed by markers of bone turnover
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model for the identification of sclerostin and its importance
in bone remodeling, but could also predict the response of
patients with osteoporosis to sclerostin inhibitors. Increases
in BMD with romosozumab treatment in animals and
humans were progressive but the slope of the increase
changed with time; a finding in line with the observations
of patients with sclerostin deficiency in whom stabilization
of the disease was invariably observed after the third
decade of life. Together these findings suggest that treat-
ment of patients with osteoporosis with sclerostin inhibitors
will be of limited duration and will form part of a treatment
strategy rather than monotherapy, particularly for patients
with severe osteoporosis.
Conclusions
Study of the genetics and pathophysiology of three very rare
skeletal disorders provided new effective interventions for
osteoporosis with different mechanisms of action. These,
together with other agents, in combination or sequentially,
will form, in our opinion, the basis of treatment of the indi-
vidual patient with osteoporosis in the future, as it occurs in
other chronic diseases. Crucial for the successful application
of these new treatments for clinical practice will be their
tolerability profile that still needs to be fully established.
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